Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | MB | P02144 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798410 | 0.88 | LMNA (0.53) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL11431434 | 0.86 | LMNA (0.52) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL18751502 | 0.86 | LMNA (0.52) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL13061725 | 0.86 | LMNA (0.52) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL3030037 | 0.86 | LMNA (0.60) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL9306137 | 0.86 | LMNA (0.47) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL23539085 | 0.84 | GAA (0.47) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL4740889 | 0.84 | CYTH2 (0.47) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL10620132 | 0.80 | LMNA (0.54) | LMNAALDH1A1GAATDP1MEN1 | |
| SCHEMBL16302253 | 0.80 | LMNA (0.54) | LMNAALDH1A1GAATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108505063-B | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyl) acetamide | 华南理工大学 | 2019-11-05 | — | — | CN | claimed |
| CN-108505063-A | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyls) acetamide | 华南理工大学 | 2018-09-07 | — | — | CN | claimed |
| CN-108505063-B | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyl) acetamide | 华南理工大学 | 2019-11-05 | — | — | CN | disclosed |
| CN-108505063-B | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyl) acetamide | 华南理工大学 | 2019-11-05 | — | — | CN | disclosed |
| CN-108505063-B | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyl) acetamide | 华南理工大学 | 2019-11-05 | — | — | CN | disclosed |
| CN-108505063-A | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyls) acetamide | 华南理工大学 | 2018-09-07 | — | — | CN | disclosed |
| CN-108505063-A | A kind of electrochemical preparation method of N- (3,5- dimethyl -4- hydroxy phenyls) acetamide | 华南理工大学 | 2018-09-07 | — | — | CN | disclosed |
| CN-102791705-B | Inverse agonist and neutral antagonist for tsh receptor | 美国政府(由卫生和人类服务部的部长所代表) | 2016-08-03 | — | — | CN | disclosed |
| US-9206154-B2 | Inverse agonists and neutral antagonists for the TSH receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206154-B2 | Inverse agonists and neutral antagonists for the TSH receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206154-B2 | Inverse agonists and neutral antagonists for the TSH receptor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2563777-A2 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120315217-A1 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-12-13 | — | — | US | disclosed |
| US-20120315217-A1 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-12-13 | — | — | US | disclosed |
| US-20120315217-A1 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-12-13 | — | — | US | disclosed |
| CN-102791705-A | Inverse agonists and neutral antagonists for the TSH receptor | US HEALTH (US) | 2012-11-21 | — | — | CN | disclosed |
| WO-2011127388-A2 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127388-A2 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315217-A1 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR | TSHR, TRHR, THRA | LMNA 4131/4885ALDH1A1 4701/4885GAA 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.